Skip to main content
. 2022 Aug 19;23(16):9355. doi: 10.3390/ijms23169355

Figure 3.

Figure 3

Schematic representation of the spectrum of action of a DYRK1A activator or inhibitor on the development of neurological (in green) and other diseases (in brown) in humans. Pathologies are labeled with a green cross if DYRK1A activation is a potential therapeutic solution and with a red line if DYRK1A inhibition is a potential solution.